Investors might want to bet on Vascular Biogenics (VBLT), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Vascular Biogenics Ltd. (NASDAQ:VBLT) shareholders should be happy to see the share price up 18% in the last month. But that is meagre solace in the face of the shocking decline over three years. To ...

Vascular Biogenics Ltd (NASDAQ:VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec in platinum-resistant ovarian cancer did not meet ...

In the annals of botched IPOs, there's the BATS disaster, and there's Facebook's notorious debut, but the train wreck that is Vascular Biogenics' IPO stands alone. The company priced its IPO on Nasdaq ...

Vascular Biogenics (VBLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago. These figures ...

It was the IPO that wasn't: A biotech firm hit the market and traded for six days, only to announce Friday that it wasn't issuing shares after all, thanks to a key investor's failure to follow through ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vascular ...